PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Some net income increase while AXSM is negative at -72.32%. John Neff would see a short-term edge over the struggling competitor.
7.12%
Some D&A expansion while AXSM is negative at -1.88%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
Both cut yoy SBC, with AXSM at -11.21%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-21.66%
Both reduce yoy usage, with AXSM at -77.82%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both negative yoy AP, with AXSM at -259.27%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
161.21%
Lower 'other working capital' growth vs. AXSM's 347.01%. David Dodd would see fewer unexpected short-term demands on cash.
200.00%
Some yoy increase while AXSM is negative at -11.02%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
22.87%
Some CFO growth while AXSM is negative at -14.77%. John Neff would note a short-term liquidity lead over the competitor.
-183.51%
Negative yoy CapEx while AXSM is 33.87%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
We reduce yoy invests while AXSM stands at 33.87%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
Negative yoy issuance while AXSM is 1493.05%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.